Pharma Manufacturing Software Problems: The 7 That Delay Batch Release, and How to Fix Them

Why does the scope stop at the electronic batch record?

Because the paper is the visible pain. A record arrives at quality assurance as a couple of hundred printed pages, a reviewer spends the best part of a day on it, and roughly three in ten go back to production for good documentation practice corrections. Everyone can describe that, so the requirement becomes replace the paper.

What gets left out is everything that decides how long release takes once the paper is gone. The deviation evidence layer, which is where an investigator currently spends thirty to forty-five hours per major event assembling screenshots into a document. The change control dependency graph, which is why nobody can answer what a supplier change touches. The annual review data path. And the exception handling that makes review by exception meaningful rather than cosmetic.

Scoping only the batch record produces a system that captures entries beautifully and still releases in nineteen days, because the delay was never in the recording. It was in the investigating and the joining.

The fix is to scope by elapsed time from last operation to disposition. Draw that path, put a duration on each hop, and for each one name the evidence required and what happens when it is missing. Then build one thing properly rather than three approximately: one product family's electronic batch record on one line, or the deviation evidence layer, or the change control graph. Sites that try all three in a first release validate none of them well.

What goes wrong when batch and material identifiers do not reconcile?

This is the failure that quietly consumes a programme, and it is almost never in a proposal.

The enterprise system knows a batch by one string, the laboratory system by another, the historian by an asset tag and a time window with no batch concept at all, and the quality system by whatever the investigator typed. Leading zeros appear and disappear. A campaign is one identifier in planning and several sublots on the floor. Equipment carries an engineering tag, a maintenance identifier and a name operators actually use, and the three do not map.

So every join is manual, and the manual join is a person. When that person is on leave, the annual review stops.

What works is establishing canonical batch identity as the first deliverable rather than a side effect. One master record that every system's identifier resolves to, mapped once at ingestion, with an explicit rule per source and a review queue for what does not resolve. Do the same for materials and equipment. Expect the exercise to surface genuine surprises, such as specifications referencing equipment decommissioned years ago, and treat those as findings to resolve rather than data to clean silently.

Sequence matters too. Master data first, then one recipe fully electronic, then rollout by line. A site converting every product at once is a site that will run paper and electronic in parallel for a year and trust neither.

Why do historian, laboratory and enterprise integrations break after launch?

Because each is a boundary owned by a different function with a different change cadence.

Historian connections break on tag changes. Automation renames a tag during a line modification, and your trend query returns nothing rather than an error, so the deviation package quietly loses its process evidence. Tag naming is owned by engineering and changes without reference to your system.

Laboratory system integrations break on schema control. If the vendor controls the schema, an upgrade can move a field, and the effort to re-establish the connection is theirs to schedule rather than yours. If you control it, a local configuration change made by a laboratory administrator can do the same thing.

Enterprise system connections break on the unglamorous details. A unit of measure conversion, a batch number with a leading zero, a partial goods movement posted differently by one site. These are the arguments that consume two weeks and never appear in an estimate.

Three defences. Automated checks that exercise each interface against the real environment daily and alert on missing or shape changed data rather than only on errors. A written interface specification agreed with the owning function, so a tag rename becomes a change request rather than a surprise. And immutable ingestion, so when a source resends corrected data you reprocess from original inputs rather than trying to unpick a partial load in a validated system.

What happens when Part 11 depth and validation strategy are not covered?

These are the two compliance gaps that convert a reasonable estimate into an overrun.

21 CFR Part 11 is not a checkbox and no software is compliant out of the box. It means an audit trail on every record, no hard deletes anywhere in the design, signature meaning and manifestation, a trusted time source, and tooling that lets a reviewer actually review audit trails rather than export them. In our experience that is several weeks of engineering that has nothing to do with your process, and it is not optional. A build that treats audit trail as a logging feature added near the end will need structural rework, because you cannot retrofit no hard deletes into a schema that has been deleting.

Validation is the other. Custom software is treated as the highest category under GAMP 5, so evidence is proportionate to that. The trap is not the evidence itself, it is the change cost afterwards. If every field addition requires a full specification cycle and witnessed execution, the software freezes while the process keeps moving, and people start running the real process in a spreadsheet next to the validated system. That spreadsheet is the data integrity risk the validated system existed to remove.

Build the evidence into the pipeline. Requirements live as traceable identifiers in the repository, each with automated tests that run on every commit and emit a timestamped execution record tied to the code version. Split by risk, the way GAMP 5 and Computer Software Assurance thinking allow: release decisions, electronic signature, audit trail and dose calculations get scripted witnessed testing, while a report filter gets automated evidence and a written rationale. The auditor receives more evidence than before, not less.

Should you build custom or configure what you already own?

Configure if you are a single site with one dosage form and modest batch volume, and your process resembles the model the vendor's other customers run. MasterControl and Werum PAS-X are strong products with a validation history you would otherwise fund yourself.

And buy document control and training records regardless of your size. Nobody should build a procedure repository or a training matrix. Veeva Vault QualityDocs and MasterControl solve that better than you will, and it is not where your margin lives. A hybrid is the normal end state rather than a compromise: keep the document and training platform, keep the laboratory system, and build the layer that is genuinely yours, which is execution, evidence and release.

Build when three or more of these are true. You are running the real process in a spreadsheet next to the validated system. You have paid a vendor for a change request twice in eighteen months just to add a field. Your differentiator has nowhere to live in the vendor's data model, such as a contract manufacturer with a per client data set or a therapy where the batch is one patient. Your release cycle exceeds a few days after the last operation for paperwork reasons rather than testing reasons. Or you run several sites that each configured the same vendor system differently, so you cannot compare them.

How do hidden costs get into the quote?

Validation scope is the first and largest. Budget a substantial share of the programme for traceability, risk assessment, evidence and a computer system validation lead. If your quality unit refuses a risk based split and insists on fully scripted testing for every function, the programme runs longer and costs proportionally more, and that decision belongs to them rather than to your developer.

Part 11 depth is second, for the reasons above, and it is frequently absorbed into a line called security.

Integrations are third, and they should be priced individually by interface rather than as one figure. Enterprise, historian and laboratory are three different problems, and direct equipment or serialisation line integration is where estimates die. Get the equipment vendor's interface specification in writing before you sign anything.

Fourth, sterile and Annex 1 scope, which adds materially over solid dose because the environmental and intervention evidence requirements are broader.

Fifth, multi site release models. Two sites with different release authorities means two release workflows plus a data residency conversation, not one workflow with a location field.

Sixth, master data reconciliation, described above, which is the overrun we see most often and the line most proposals omit entirely.

What separates a GMP build that works from one that fails here?

First, the team can speak the domain before they quote. Make them draw your data model on a whiteboard: batch, lot, sublot, campaign, phase, equipment, material, and the difference between a specification, a limit and an alert level. If you have to explain those terms, they will learn on your budget and the mistakes will be structural rather than cosmetic.

Second, the model assists rather than decides. Pre-reviewing scanned records for blanks and out of sequence timestamps, drafting deviation narratives from historian and laboratory data, and searching years of prior events for similar cases are all defensible, because a qualified human remains the recorded reviewer and signer and the output goes in as a versioned attachment with traceable inputs. Anything that makes or implies the disposition decision is an argument with your inspector that you do not need.

Third, validation evidence is a named deliverable with a named author. A real answer lists a user requirement specification with a traceability matrix, a functional risk assessment, qualification evidence or a documented automated equivalent with rationale, and a validation lead who has sat across a table from an investigator. Support your quality team with the documents means you pay twice.

Fourth, the exit is settled on day one. Source code, database schema, infrastructure definitions and the validation package sit in your repository and your cloud account from the first sprint rather than being handed over at completion. In a category where your software is inspected evidence, whoever holds the code holds your batch release.